10. Feb 2017
1. Feb 2017
31. Jan 2017
EUCODIS Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and EUCODIS now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.
24. Jan 2017
IBG Beteiligungsgesellschaft Sachsen-Anhalt GmbH, a wholly-owned subsidiary of the state of Saxony-Anhalt, has launched the new venture capital fund RKF III with a volume of EUR 50 million.
9. Jan 2017
The Supervisory Board of bmp Beteiligungsmanagement AG ("bmp") has appointed Dr. Jan Alberti to the Management Board as of January 1, 2017. He now runs the company together with Oliver Borrmann and Andreas van Bon.
Dr. Jan Alberti will be dedicated to new acquisitions and business development of portfolio companies as well as to the acquisition of new fund mandates and will be responsible for marketing.
8. Dec 2016
16. Nov 2016
Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today the first results of a preclinical study in an AD mouse model with the pyroglutamate-3 Abeta (pGlu3-Abeta)-specific antibody mPBD-C06, comparing versions with and without a mutation eliminating complement activation which will be presented as a poster at the Society for Neuroscience (SfN) meeting on 16 November 2016 in San Diego, CA.
7. Sep 2016
7. Sep 2016
30. Jun 2016
License and supply agreement is based on Crossbeta's proprietary technology and supports Probiodrug's biomarker development activities